• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer.

作者信息

Mayer Erica L

机构信息

Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

出版信息

JACC CardioOncol. 2020 Jun 16;2(2):190-192. doi: 10.1016/j.jaccao.2020.05.001. eCollection 2020 Jun.

DOI:10.1016/j.jaccao.2020.05.001
PMID:34396228
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8352194/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/668e/8352194/9a9f1ee1bec3/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/668e/8352194/9a9f1ee1bec3/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/668e/8352194/9a9f1ee1bec3/fx1.jpg

相似文献

1
Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer.携手团队优化HER2阳性乳腺癌患者的护理
JACC CardioOncol. 2020 Jun 16;2(2):190-192. doi: 10.1016/j.jaccao.2020.05.001. eCollection 2020 Jun.
2
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.曲妥珠单抗应用前后 HER2 阳性早期乳腺癌患者的密集化疗：GIM2 试验的探索性分析。
Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4.
3
New developments in the treatment of HER2-positive breast cancer.HER2阳性乳腺癌治疗的新进展。
Breast Cancer (Dove Med Press). 2012 May 1;4:53-64. doi: 10.2147/BCTT.S24976.
4
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.曲妥珠单抗-德鲁替康：一种用于治疗 HER2 阳性乳腺癌的研究药物。
Expert Opin Investig Drugs. 2020 Sep;29(9):901-910. doi: 10.1080/13543784.2020.1792443. Epub 2020 Jul 23.
5
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.赫敏：一项随机2期试验，比较MM - 302联合曲妥珠单抗与医生选择的化疗方案联合曲妥珠单抗，用于治疗既往接受过治疗、未使用过蒽环类药物、HER2阳性、局部晚期/转移性乳腺癌患者。
BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z.
6
LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.LMO4介导HER2阳性乳腺癌细胞中的曲妥珠单抗耐药性。
Am J Cancer Res. 2018 Apr 1;8(4):594-609. eCollection 2018.
7
Trastuzumab and survival of patients with metastatic breast cancer.曲妥珠单抗与转移性乳腺癌患者的生存率
Arch Gynecol Obstet. 2017 Aug;296(2):303-312. doi: 10.1007/s00404-017-4421-x. Epub 2017 Jun 14.
8
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.89Zr-曲妥珠单抗 PET/CT 检测人表皮生长因子受体 2 阴性原发性乳腺癌患者中人类表皮生长因子受体 2 阳性转移灶
Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820.
9
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.曲妥珠单抗-德鲁替康（DS-8201a）治疗既往接受过曲妥珠单抗-美坦新偶联物治疗的晚期 HER2 阳性乳腺癌患者：一项剂量扩展、I 期研究。
Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
10
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.磷酸化HER2在接受辅助曲妥珠单抗治疗的HER2阳性乳腺癌患者中的预后价值。
Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

本文引用的文献

1
Cardiology Involvement in Patients with Breast Cancer Treated with Trastuzumab.曲妥珠单抗治疗的乳腺癌患者的心脏受累情况
JACC CardioOncol. 2020 Jun;2(2):179-189. doi: 10.1016/j.jaccao.2020.04.010. Epub 2020 Jun 16.
2
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.癌症患者在肿瘤治疗全程中心血管疾病的管理：ESMO 共识推荐。
Ann Oncol. 2020 Feb;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023.
3
Preparing the Cardiovascular Workforce to Care for Oncology Patients: JACC Review Topic of the Week.
为肿瘤患者提供心血管保健服务：JACC 本周综述主题。
J Am Coll Cardiol. 2019 May 7;73(17):2226-2235. doi: 10.1016/j.jacc.2019.02.041.
4
Breast Cancer Treatment: A Review.乳腺癌治疗：综述。
JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323.
5
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关致死性心肌炎报告增加。
Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.
6
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.卡非佐米相关心血管不良事件：系统评价和荟萃分析。
JAMA Oncol. 2018 Mar 8;4(3):e174519. doi: 10.1001/jamaoncol.2017.4519.
7
HER2-positive breast cancer.人表皮生长因子受体 2 阳性乳腺癌。
Lancet. 2017 Jun 17;389(10087):2415-2429. doi: 10.1016/S0140-6736(16)32417-5. Epub 2016 Dec 7.
8
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.成人癌症幸存者心功能障碍的预防和监测：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5.
9
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.多学科方法在心血管肿瘤学研究中的新型治疗方法（MANTICORE 101-乳腺）：预防曲妥珠单抗相关心脏毒性的随机试验。
J Clin Oncol. 2017 Mar 10;35(8):870-877. doi: 10.1200/JCO.2016.68.7830. Epub 2016 Nov 28.
10
Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.评估基线心脏功能筛查在早期乳腺癌治疗中的效用。
Oncologist. 2016 Jun;21(6):666-70. doi: 10.1634/theoncologist.2015-0449. Epub 2016 Apr 22.